Recombinant activated factor VII (RFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices.

This is a new open-label study, which showed efficacy of rFVIIa in normalising prothrombin time and effective
control of bleeding esophageal varices in cirrhotic patients, in addition to
safety in using rFVIIa.

– M. Aldouri.